[HTML][HTML] Breast cancer: miRNAs monitoring chemoresistance and systemic therapy

S Singh, H Saini, A Sharma, S Gupta… - Frontiers in …, 2023 - frontiersin.org
With a high mortality rate that accounts for millions of cancer-related deaths each year,
breast cancer is the second most common malignancy in women. Chemotherapy has …

Breast cancer: miRNAs monitoring chemoresistance and systemic therapy

S Singh, H Saini, A Sharma, S Gupta, V Huddar… - Frontiers in …, 2023 - europepmc.org
With a high mortality rate that accounts for millions of cancer-related deaths each year,
breast cancer is the second most common malignancy in women. Chemotherapy has …

[HTML][HTML] Breast cancer: miRNAs monitoring chemoresistance and systemic therapy

S Singh, H Saini, A Sharma, S Gupta… - Frontiers in …, 2023 - ncbi.nlm.nih.gov
With a high mortality rate that accounts for millions of cancer-related deaths each year,
breast cancer is the second most common malignancy in women. Chemotherapy has …

[PDF][PDF] Breast cancer: miRNAs monitoring chemoresistance and systemic therapy

S Singh, H Saini, A Sharma, S Gupta, VG Huddar… - 2023 - researchgate.net
3. Targeting miRNAs—either reducing or raising their expression—seems to be an attractive
approach for designing novel, more effective, and personalized treatments for breast cancer …

Breast cancer: miRNAs monitoring chemoresistance and systemic therapy

S Singh, H Saini, A Sharma, S Gupta… - Frontiers in …, 2023 - pubmed.ncbi.nlm.nih.gov
With a high mortality rate that accounts for millions of cancer-related deaths each year,
breast cancer is the second most common malignancy in women. Chemotherapy has …

Breast cancer: miRNAs monitoring chemoresistance and systemic therapy.

S Singh, H Saini, A Sharma, S Gupta… - Frontiers in …, 2023 - europepmc.org
With a high mortality rate that accounts for millions of cancer-related deaths each year,
breast cancer is the second most common malignancy in women. Chemotherapy has …